Eye drops and surface damage in glaucoma treatment
Part of Eyes & vision clinical trials.
This study looks at how certain glaucoma eye drops affect the surface of your eye. It tests a new implant that may reduce damage and improve comfort.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have open-angle glaucoma or are suspected of having it in one eye.
- In that eye, you have had cataract surgery (lens replaced) with a certain level of support for the new lens.
- You have used glaucoma eye drops for at least 6 months, with no more than 3 drops a day, including a specific drop at night.
- You have missed less than 20% of your eye drop doses in the last month and took your last dose within the past 24 hours.
- You have small scratches on the surface of your eye (corneal erosions) as seen by your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new implant that releases medicine for glaucoma while you have cataract surgery. It may help lower eye pressure without using daily drops.
This trial tests if a bimatoprost implant placed during cataract surgery (combined with a special lens) can lower eye pressure better than standard timolol eye drops. It may help people with mild to moderate glaucoma or high eye pressure who are already planning cataract surgery.
This trial tests a small, flexible ring placed in the eye that slowly releases a medicine (bimatoprost) to lower eye pressure, for people with open-angle glaucoma or ocular hypertension. It might offer a longer-lasting alternative to daily eye drops.
This study looks at how long-term use of glaucoma eye drops may affect the surface of the eye (the clear front layer). It aims to find out if these drops cause dry-eye or other surface problems, which can help doctors better manage treatment.
This Phase 3 study compares two versions of the same glaucoma eye-drop medicine (bimatoprost 0.01%) to see how similarly they work and their effect on eye pressure. It may help people with chronic open-angle glaucoma or ocular hypertension who need treatment in both eyes.
This study measures inflammation markers on the eye surface in people with primary open-angle glaucoma or ocular hypertension who use certain glaucoma drops. The results may help doctors understand how these drops affect the eye and inflammation.
Hear when a new Glaucoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.